Contact information
Type
Scientific
Primary contact
Dr Harald Murck
ORCID ID
Contact details
Laxdale Ltd
Kings Park House
Laurelhill Business Park
Polmaise Road
Stirling
FK7 9JQ
United Kingdom
+44 (0)1786 476001
hmurck@laxdale.co.uk
Additional identifiers
EudraCT number
ClinicalTrials.gov number
Protocol/serial number
LA01.01.0005
Study information
Scientific title
Acronym
Study hypothesis
Not provided at time of registration
Ethics approval
Not provided at time of registration
Study design
Randomised controlled trial
Primary study design
Interventional
Secondary study design
Randomised controlled trial
Trial setting
Not specified
Trial type
Not Specified
Patient information sheet
Condition
Huntington's disease
Intervention
Two groups randomly allocated to placebo or 2 g/day ethyl EPA on a double blind basis.
Patients who completed the 12 month randomisation phase of the trial were invited to take part in a further 12 month open label phase receiving 2 g/day Ethyl EPA.
Intervention type
Other
Phase
Not Specified
Drug names
Primary outcome measures
Not provided at time of registration
Secondary outcome measures
Not provided at time of registration
Overall trial start date
01/01/2003
Overall trial end date
01/01/2004
Reason abandoned
Eligibility
Participant inclusion criteria
1. Written informed consent
2. Availability of a responsible family member or carer to look after the patient during the trial and ensure complete compliance
3. Diagnosis of HD in stage I
Participant type
Patient
Age group
Not Specified
Gender
Not Specified
Target number of participants
Not provided at time of registration
Participant exclusion criteria
Not provided at time of registration
Recruitment start date
01/01/2003
Recruitment end date
01/01/2004
Locations
Countries of recruitment
United Kingdom
Trial participating centre
Laxdale Ltd
Stirling
FK7 9JQ
United Kingdom
Sponsor information
Organisation
Laxdale Ltd (UK)
Sponsor details
Kings Park House
Laurelhill Business Park
Polmaise Road
Stirling
FK7 9JQ
United Kingdom
+44 (0)1786 476001
admin@Laxdale.co.uk
Sponsor type
Industry
Website
Funders
Funder type
Industry
Funder name
Laxdale Ltd (UK)
Alternative name(s)
Funding Body Type
Funding Body Subtype
Location
Results and Publications
Publication and dissemination plan
Not provided at time of registration
Intention to publish date
Participant level data
Not provided at time of registration
Results - basic reporting
Publication summary
1. 2005 results in http://www.ncbi.nlm.nih.gov/pubmed/16043801
Publication citations
-
Results
Puri BK, Leavitt BR, Hayden MR, Ross CA, Rosenblatt A, Greenamyre JT, Hersch S, Vaddadi KS, Sword A, Horrobin DF, Manku M, Murck H, Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial., Neurology, 2005, 65, 2, 286-292, doi: 10.1212/01.wnl.0000169025.09670.6d.